Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.
We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment.
In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...
1don MSN
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Deutsche Bank lowered the firm’s price target on Sarepta (SRPT) to $99 from $124 and keeps a Hold rating on the shares after the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results